Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).

被引：34
作者：
Usmani, Saad Zafar
Mateos, Maria-Victoria
Nahi, Hareth
Krishnan, Amrita Y.
van de Donk, Niels W. C. J.
San Miguel, Jesus
Oriol, Albert
Rosinol, Laura
Chari, Ajai
Adams, Homer
Girgis, Suzette
Lin, Shun Xin Wang
Stephenson, Tara
Kemmerer, Kristy
Smit, Jennifer
Elsayed, Yusri A.
Infante, Jeffrey R.
Goldberg, Jenna D.
Banerjee, Arnob
Garfall, Alfred L.
机构：
[1] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[2] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[3] Karolinska Inst, Stockholm, Sweden
[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden
[5] City Hope Natl Med Ctr, Duarte, CA USA
[6] Vrije Univ Amsterdam Med Ctr, Amsterdam Univ, Med Ctr, Amsterdam, Netherlands
[7] Clin Univ Navarra, Pamplona, Spain
[8] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[9] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[10] Hosp Clin Barcelona, Barcelona, Spain
[11] Mt Sinai Sch Med, Dept Hematol Oncol, New York, NY USA
[12] Janssen Res & Dev LLC, Spring House, PA USA
[13] Janssen Res & Dev LLC, Raritan, NJ USA
[14] Perelman Sch Med, Philadelphia, PA USA
[15] Abramson Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
10.1200/JCO.2020.38.15_suppl.100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：2
相关论文
共 50 条
[31]   Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) [J].
Lesokhin, Alexander M. ;
Levy, Moshe Y. ;
Dalovisio, Andrew P. ;
Bahlis, Nizar J. ;
Solh, Melhem ;
Sebag, Michael ;
Jakubowiak, Andrzej ;
Jethava, Yogesh S. ;
Costello, Caitlin L. ;
Chu, Michael P. ;
Savona, Michael R. ;
Gasparetto, Cristina ;
Trudel, Suzanne ;
Chou, Jeffrey ;
Udata, Chandrasekhar ;
Basu, Cynthia ;
Krupka, Heike I. ;
Raje, Noopur S. .
BLOOD, 2020, 136
[32]   Anti-CD3/B-Cell Maturation Antigen Bispecific Antibody CM336 in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase I/II Study [J].
An, Gang ;
Huang, Zhongxia ;
Liang, Aibin ;
Fang, Baijun ;
Jing, Hongmei ;
Qiu, Lu-Gui .
BLOOD, 2024, 144 :3377-3377
[33]   A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody). [J].
Rodriguez-Otero, Paula ;
D'Souza, Anita ;
Reece, Donna Ellen ;
van de Donk, Niels W. C. J. ;
Chari, Ajai ;
Krishnan, Amrita Y. ;
Martin, Thomas G. ;
Mateos, Maria-Victoria ;
Morillo, Daniel ;
Hurd, David Duane ;
Rosinol, Laura ;
Balari, Anna Sureda ;
Wasch, Ralph ;
Vishwamitra, Deeksha ;
Lin, Shun Xin Wang ;
Prior, Thomas ;
Vandenberk, Lien ;
Smit, Marie-Anne Damiette ;
Rocafiguera, Albert Oriol ;
Dholaria, Bhagirathbhai R. .
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[34]   Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma [J].
Hoeynck, Brian ;
Hwang, Wei-Ting ;
Garfall, Alfred L. ;
Susanibar-Adaniya, Sandra Patricia ;
Vogl, Dan T. ;
Waxman, Adam ;
Stadtmauer, Edward A. ;
Cohen, Adam D. .
BLOOD, 2022, 140 :10081-10083
[35]   B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma [J].
Abramson, Hanley N. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) :1-24
[36]   Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma [J].
Peng, Fengping ;
Wang, Yuan ;
Zhao, Jiliang ;
Liu, Hui ;
Liu, Zhaoyun ;
Ding, Kai ;
Zhang, Hongkai ;
Fu, Rong .
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) :417-421
[37]   A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma [J].
Kumar, Shaji ;
D'Souza, Anita ;
Shah, Nina ;
Rodriguez, Cesar ;
Voorhees, Peter M. ;
Bueno, Orlando F. ;
Ben Buelow ;
Freise, Kevin J. ;
Yue, Susan ;
Pothacamury, Rajvineeth Kumar ;
Polepally, Akshanth R. ;
Vij, Ravi .
BLOOD, 2021, 138
[38]   Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma [J].
Pillarisetti, Kodandaram ;
Powers, Gordon ;
Luistro, Leopoldo ;
Babich, Alexander ;
Baldwin, Eric ;
Li, Yingzhe ;
Zhang, Xiaochun ;
Mendonca, Mark ;
Majewski, Nate ;
Nanjunda, Rupesh ;
Chin, Diana ;
Packman, Kathryn ;
Elsayed, Yusri ;
Attar, Ricardo ;
Gaudet, Francois .
BLOOD ADVANCES, 2020, 4 (18) :4538-4549
[39]   A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma [J].
Lesokhin, Alexander M. ;
Raje, Noopur ;
Gasparetto, Cristina J. ;
Walker, Justine ;
Krupka, Heike I. ;
Joh, Tenshang ;
Taylor, Carrie T. ;
Jakubowiak, Andrzej .
BLOOD, 2018, 132
[40]   MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM) [J].
Dholaria, Bhagirathbhai ;
Bahlis, Nizar ;
Raje, Noopur ;
Costello, Caitlin ;
Solh, Melhem ;
Levy, Moshe ;
Tomasson, Michael ;
Dube, Harman ;
Damore, Michael ;
Lon, Hoi Kei ;
Basu, Cynthia ;
Skoura, Athanasia ;
Chan, Edward ;
Trudel, Suzanne ;
Jakubowiak, Andrzej ;
Chu, Michael ;
Gasparetto, Cristina ;
Dalovisio, Andrew ;
Sebag, Michael ;
Lesokhin, Alexander .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 :S17-S17
12345